💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Raltegravir Potassium

CHEMBL518520 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
482.5 g/mol
LogP
—
Phase
4

The potassium salt formulation of raltegravir used in combination with other antiretroviral drugs to suppress HIV replication and maintain immune function. It is well-tolerated and has a favorable drug interaction profile compared to some older HIV medications.

Molekularmasse

482,5000 g/mol

TPSA

153,00 Ų

Therapeutische Bereiche

Osteoporosis Generalized Anxiety Disorder Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Hyperlipidemia Lymphoma HIV/AIDS Hepatitis C Tuberculosis Cardiovascular Disease Leukemia

Wirkmechanismus

Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c([O-])c(=O)n2C)o1.[K+]

                

                

                
                

                    
InChI

                    
InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H20FKN6O5

                    

                    
                    

                        
HBD / HBA

                        
2 / 9

                    

                    
                    

                        
Rotierbare Bindungen

                        
6

                    

                    
                    
                    

                        
Schwere Atome

                        
33

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
The potassium salt formulation of raltegravir used in combination with other antiretroviral drugs to suppress HIV replication and maintain immune function. It is well-tolerated and has a favorable drug interaction profile compared to some older HIV medications.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Raltegravir Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL518520.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 23668479.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.